New Lancet study describes which cancer patients are more vu
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The study, published in Lancet Oncology found that blood cancer patients were particularly at risk with 57% higher odds of severe disease if they contract COVID-19. This was when compared to other cancer patients, such as breast cancer, which was shown to have the lowest risk overall.

Researchers compared adult patients with cancer enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) cohort, with a parallel non-COVID-19 UK cancer control population from the UK Office for National Statistics. The primary outcome of the study was the effect of primary tumour subtype, age, and sex and on SARS-CoV-2 prevalence and the case–fatality rate during hospital admission. They analysed the effect of tumour subtype and patient demographics (age and sex) on prevalence and mortality from COVID-19 using univariable and multivariable models.

-- 319 of 1044 patients in the UKCCMP cohort died, 295 of whom had a cause of death recorded as due to COVID-19.
-- The all-cause case–fatality rate in patients with cancer after SARS-CoV-2 infection was significantly associated with increasing age, rising from 0·10 in patients aged 40–49 years to 0·48 in those aged 80 years and older.
-- Patients with haematological malignancies (leukaemia, lymphoma, and myeloma) had a more severe COVID-19 trajectory compared with patients with solid organ tumours.
-- Compared with the rest of the UKCCMP cohort, patients with leukaemia showed a significantly increased case–fatality rate.
-- After correction for age and sex, patients with haematological malignancies who had recent chemotherapy had an increased risk of death during COVID-19-associated hospital admission.

These results could be useful to assist physicians in informed risk–benefit discussions to explain COVID-19 risk and enable an evidenced-based approach to national social isolation policies.